Lixte Biotechnology Holdings, Inc.
Price Action
Technical Summary
EMERGING TRENDLixte Biotechnology Holdings, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 95), indicating clear outperformance against the broad market. Earnings growth of 38% provides fundamental context to the price action. However, price is extended 31% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $6.93 | +3.74% | ABOVE |
| 50 SMA | $5.50 | +30.77% | ABOVE |
| 100 SMA | $4.23 | +69.91% | ABOVE |
| 150 SMA | $4.12 | +74.67% | ABOVE |
| 200 SMA | $4.27 | +68.25% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is LIXT in an uptrend right now?
LIXT has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is LIXT overbought or oversold?
LIXT's RSI (14) is 53. The stock is in neutral territory, neither overbought nor oversold.
Is LIXT outperforming the market?
LIXT has a Relative Strength (RS) Rating of 95 out of 99. Yes, LIXT is a market leader, outperforming 95% of all stocks over the past 12 months.
Where is LIXT in its 52-week range?
LIXT is trading at $7.19, which is 92% of its 52-week high ($7.78) and 92% above its 52-week low ($0.68).
How volatile is LIXT?
LIXT has a Beta of 1.03 and 52-week volatility of 145%. It's more volatile than the S&P 500 - expect bigger swings.